Academic Journal

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

التفاصيل البيبلوغرافية
العنوان: Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
المؤلفون: Kok, Chung H., Saunders, Verity A., Dang, Phuong, Shanmuganathan, Naranie, White, Deborah, Branford, Susan, Yeung, David, Hughes, Timothy P.
المساهمون: Department of Health | National Health and Medical Research Council, Cancer Council South Australia
المصدر: Blood Cancer Journal ; volume 13, issue 1 ; ISSN 2044-5385
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2023
الوصف: Variability in the molecular response to frontline tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia may be partially driven by differences in the level of kinase inhibition induced. We measured in vivo BCR::ABL1 kinase inhibition (IVKI) in circulating mononuclear cells after 7 days of therapy. In 173 patients on imatinib 600 mg/day, 23% had low IVKI (<11% reduction in kinase activity from baseline); this was associated with higher rates of early molecular response (EMR) failure; lower rates of major molecular response (MMR), and MR4.5 by 36 months, compared to high IVKI patients. Low IVKI was more common (39%) in patients with large spleens (≥10 cm by palpation). Notably 55% of patients with large spleens and low IVKI experienced EMR failure whereas the EMR failure rate in patients with large spleens and high IVKI was only 12% ( p = 0.014). Furthermore, patients with large spleen and low IVKI had a higher incidence of blast crisis, inferior MMR, MR4.5, and event-free survival compared to patients with large spleen and high IVKI and remaining patients. In nilotinib-treated patients ( n = 73), only 4% had low IVKI. The combination of low IVKI and large spleen is associated with markedly inferior outcomes and interventions in this setting warrant further studies.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1038/s41408-023-00917-4
الاتاحة: http://dx.doi.org/10.1038/s41408-023-00917-4
https://www.nature.com/articles/s41408-023-00917-4.pdf
https://www.nature.com/articles/s41408-023-00917-4
Rights: https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0
رقم الانضمام: edsbas.E6B02BDA
قاعدة البيانات: BASE
الوصف
DOI:10.1038/s41408-023-00917-4